Literature DB >> 19996074

The natural history of primary progressive multiple sclerosis.

Marcus Koch1, Elaine Kingwell, Peter Rieckmann, Helen Tremlett.   

Abstract

BACKGROUND: Primary progressive multiple sclerosis (PPMS) carries the worst prognosis of the multiple sclerosis (MS) subtypes and is currently untreatable. A previous analysis of the British Columbia MS database challenged the view that disability progression is rapid in PPMS, but identified few predictors of disease progression. Here, we extend previous analyses in an updated PPMS retrospective cohort study of prevalent cases.
METHODS: We used Kaplan-Meier survival analyses and Cox regression models to investigate the influence of gender, age at onset, and onset symptoms on time to and age at Expanded Disability Status Scale (EDSS) 6.0 in patients with PPMS.
RESULTS: Of 5,779 patients with definite MS, 552 (10%) had PPMS. Median time to EDSS 6.0 was 14.0 years (95% confidence interval [CI] 11.3-16.7), reached at a median age of 58.6 years (95% CI 56.8-60.3). Sensory onset symptoms were associated with a longer time to and an older age at EDSS 6.0 (multivariable hazard ratios 0.55 [95% CI 0.35-0.87] and 0.54 [0.35-0.85]). Younger age at disease onset was associated with a longer time to but a younger age at EDSS 6.0. Gender and other onset symptoms were not associated with these outcomes. Fifty patients with PPMS (9%) fulfilled criteria for benign MS (EDSS < or =3.0 after 10 years' disease duration).
CONCLUSIONS: We identified 2 predictors of a slower disease progression in primary progressive multiple sclerosis. Sensory onset symptoms were associated with both a longer time to and a higher age at Expanded Disability Status Scale (EDSS) 6.0. A younger age at disease onset was associated with a longer time to EDSS 6.0, but patients with an early disease onset reached EDSS 6.0 at a younger age.

Entities:  

Mesh:

Year:  2009        PMID: 19996074     DOI: 10.1212/WNL.0b013e3181c5b47f

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  40 in total

Review 1.  Epigenetics of multiple sclerosis: an updated review.

Authors:  Cem İsmail Küçükali; Murat Kürtüncü; Arzu Çoban; Merve Çebi; Erdem Tüzün
Journal:  Neuromolecular Med       Date:  2014-03-21       Impact factor: 3.843

2.  Ovarian aging is associated with gray matter volume and disability in women with MS.

Authors:  Jennifer S Graves; Roland G Henry; Bruce A C Cree; Geralyn Lambert-Messerlian; Ruth M Greenblatt; Emmanuelle Waubant; Marcelle I Cedars; Alyssa Zhu; Peter Bacchetti; Stephen L Hauser; Jorge R Oksenberg
Journal:  Neurology       Date:  2017-12-22       Impact factor: 9.910

Review 3.  The role of glial-neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain.

Authors:  Rachel R Robinson; Alina K Dietz; Asif M Maroof; Reto Asmis; Thomas G Forsthuber
Journal:  Immunotherapy       Date:  2019-02       Impact factor: 4.196

4.  Aging-Exacerbated Acute Axon and Myelin Injury Is Associated with Microglia-Derived Reactive Oxygen Species and Is Alleviated by the Generic Medication Indapamide.

Authors:  Nathan J Michaels; Kennedy Lemmon; Jason R Plemel; Samuel K Jensen; Manoj K Mishra; Dennis Brown; Khalil S Rawji; Marcus Koch; V Wee Yong
Journal:  J Neurosci       Date:  2020-10-15       Impact factor: 6.167

Review 5.  Epigenetic changes in patients with multiple sclerosis.

Authors:  Marcus W Koch; Luanne M Metz; Olga Kovalchuk
Journal:  Nat Rev Neurol       Date:  2012-11-20       Impact factor: 42.937

Review 6.  New and emerging immune-targeted drugs for the treatment of multiple sclerosis.

Authors:  Alan M Palmer
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

7.  Thyroid hormone alleviates demyelination induced by cuprizone through its role in remyelination during the remission period.

Authors:  Mao Zhang; Xiao L Zhan; Zi Y Ma; Xing S Chen; Qi Y Cai; Zhong X Yao
Journal:  Exp Biol Med (Maywood)       Date:  2015-01-10

8.  Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.

Authors:  Marita Zimmermann; Elizabeth Brouwer; Jeffrey A Tice; Matt Seidner; Anne M Loos; Shanshan Liu; Richard H Chapman; Varun Kumar; Josh J Carlson
Journal:  CNS Drugs       Date:  2018-12       Impact factor: 5.749

Review 9.  Treatment trials in progressive MS--current challenges and future directions.

Authors:  Marcus W Koch; Gary Cutter; Peter K Stys; V Wee Yong; Luanne M Metz
Journal:  Nat Rev Neurol       Date:  2013-07-30       Impact factor: 42.937

10.  Healthcare resources utilisation in primary progressive multiple sclerosis.

Authors:  Carlo Piccinni; Giulia Ronconi; Silvia Calabria; Letizia Dondi; Emanuele Forcesi; Elisa Rossi; Antonella Pedrini; Nello Martini
Journal:  Neurol Sci       Date:  2018-04-10       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.